The KLF13 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the KLF13 gene in the HT29 human colorectal adenocarcinoma cell line. This heterogeneous pool carries diverse loss-of-function mutations, providing a robust model for studying KLF13 function without the biases of single-cell cloning. The cells are supplied as a validated, ready-to-use culture suitable for cancer biology and signaling research.
HT29 cells originate from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female. These adherent epithelial cells retain key intestinal features, including mucin production and differentiation capacity under appropriate conditions. Widely used for colon cancer, drug transport, and differentiation studies, HT29 cells respond to TGF-?? and other growth factors, offering a relevant background for examining transcriptional regulation in gastrointestinal malignancies.
KLF13 encodes a zinc-finger transcription factor acting downstream of TGF-??/Smad and Notch pathways. In colorectal epithelia, it represses proliferation by inhibiting CCND1 and inducing CDKN1A, while modulating apoptosis through BCL2 and BAX. KLF13 interacts with cofactors HDAC1, HDAC2, mSin3A, p300/CBP, and Smad3, and is regulated by Smad2/3, Notch1, E2F1, and miR-125b. Disruption of KLF13 thus releases key brakes on cell cycle progression and survival, yielding a loss-of-function model for mechanistic studies.
In HT29 cells, KLF13 knockout enables dissection of its tumor-suppressive role in colorectal cancer. Loss of KLF13 may accelerate proliferation, diminish TGF-??-induced cytostasis, and lower apoptotic thresholds, reflecting oncogenic processes. The endogenous TGF-?? receptor system in HT29 provides a physiological context to analyze how KLF13 ablation reprograms signaling and to identify compensatory pathways that sustain transformed phenotypes.
This knockout product supports diverse applications, including proliferation and cell cycle assays, apoptosis profiling via flow cytometry, and TGF-?? response reporter assays. It is also suited for drug resistance studies and transcriptomic analyses (RNA-seq) to map downstream gene networks. Researchers may use the cells to investigate immune-related cytokine regulation, given KLF13 targets IL4 and CCL5. For further information or custom inquiries, please contact Ascent Research.
